Cowen & Co. Reaffirms Their Buy Rating on Rhythm Pharmaceuticals Inc (RYTM)

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) today and set a price target of $40. The company’s shares opened today at $29.76.

According to, Nadeau is a 5-star analyst with an average return of 12.4% and a 55.7% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Rhythm Pharmaceuticals Inc is a Strong Buy with an average price target of $39.

See today’s analyst top recommended stocks >>

The company has a one-year high of $37.23 and a one-year low of $16.80. Currently, Rhythm Pharmaceuticals Inc has an average volume of 201.6K.

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RYTM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.